Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Shenoy, K. C. Kwon, A. Rathinasabapathy, S. Lin, G. Jin, C. Song, P. Shil, A. Nair, Y. Qi, Q. Li, J. Francis, M. Katovich, H. Daniell, M. Raizada (Gainesville, Philadelphia, Baton Rouge, United States Of America). Oral delivery of transplastomic plant derived angiotensin converting enzyme2 - a novel approach for pulmonary hypertension therapeutics. Eur Respir J 2014; 44: Suppl. 58, 3425

Member's Comments

No comment yet.

Related content which might interest you: Nebivolol and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Smad1 deficiency and female gender contribute to the development of pulmonary hypertension Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 The flavonoid quercetin reverses monocrotaline-induced pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Female pulmonary arterial hypertension is associated with decreased microRNA96 expression Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Immune signatures in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Treprostinil prodrugs for pulmonary arterial hypertension evaluated in cAMP profiling studies in live CHO-K1 cells Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Role of NMDA receptors in vascular remodelling associated to pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Intact serotonin signaling is not required for the development of severe angioproliferative pulmonary hypertension in rats Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Prolonged activity of inhaled treprostinil prodrug nanoparticles in a rat model of pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Molecular study of genetic modifiers in patients with pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Epoprostenol dosing by concomitant therapies in the PROSPECT registry Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Derivation and characterisation of endothelial cells from patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 PAH-specific therapies improve survival in patients with pulmonary arterial hypertension associated with connective tissue diseases: A Russian single centre experience Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 ASK1 promotes maladaptive remodeling in a rodent model of pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Phosphodiesterase inhibitors as promising therapies for cigarette smoke-induced emphysema and pulmonary hypertension (PH) in mice Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Treprostinil pharmacokinetics in rats are extended using inhaled prodrug formulations Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Endothelial-to-mesenchymal transition in pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Single center experience with systematic diagnostic and predictive genetic screening for pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Inflammasome ASC-knock out attenuates the development of pulmonary hypertension caused by chronic alveolar hypoxia Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014